Roiled by financial turmoil, Teva's CEO boots R&D chief, top execs in C-suite overhaul
Following news of impending layoffs and disastrous financial performance, the new CEO of generics giant Teva Pharmaceuticals is booting old executives and bringing up a new team to lead the troubled company’s restructuring efforts.
Kåre Schultz, who took the reins at Teva earlier this month, has made staffing cuts his first big move. The company is expected to soon slash 4,000 jobs at its headquarters and plants in Israel, along with some locations in the US, Calcalist reported last Thursday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.